

RNAi

Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 470 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003 and is currently incorporated in the report on gene therapy published by Jain PharmaBiotech and is regularly updated with latest edition in 2015. Prof. Jain has edited "Drug Delivery Systems" (1st ed Humana/Springer 2008, 2nd ed 2014) and Drug Delivery to the Central Nervous System (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer 2017), "Handbook of Neuroprotection" (Springer 2011), "Application of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Application of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

September 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	16
1. Technologies for suppressing gene function	18
Introduction	18
DNA transcription.....	18
RNA	18
<i>Non-coding RNA</i>	<i>18</i>
<i>RNA research and potential applications.....</i>	<i>20</i>
<i>Role of RNA in regulation of the dihydrofolate reductase gene</i>	<i>22</i>
Gene regulation	22
Post-transcriptional regulation of gene expression.....	23
Alternative RNA splicing.....	24
Technologies for gene suppression	24
Antisense oligonucleotides	24
Phosphorodiamidate morpholino oligomers.....	25
Transcription factor decoys	25
Aptamers.....	26
Ribozymes	26
Aptazymes.....	27
RNA aptamers vs allosteric ribozymes	27
Peptide nucleic acid.....	27
PNA-DNA chimeras.....	28
Locked nucleic acid	28
Long noncoding RNAs.....	28
Gene silencing	29
Post-transcriptional gene silencing	29
TargetTron™ technology for gene knockout.....	30
Definitions and terminology of RNAi	30
RNAi mechanisms	31
RNAi oligonucleotides	33
Non-promoter-associated small RNAs.....	33
Piwi-interacting RNAs in germ cell development	34
Relation of RNAi to junk DNA.....	34
RNAi and epigenetic mechanisms	35
RNA editing and RNAi	35
Historical landmarks in the development of RNAi	35
2. RNAi Technologies	38
Introduction	38
Comparison of antisense and RNAi	38
Advantages of antisense over siRNAs	38
Advantages of siRNAs over antisense	39
RNA aptamers vs siRNA	39
RNA Lassos versus siRNA.....	39
Concluding remarks on antisense vs RNAi	40
PMOs vs antisense and siRNAs	40
ssRNAi	40
Antisense vs DNP-ssRNA and DNP-siRNA	40
LNA and RNAi.....	41
LNA for gene suppression.....	41
Comparison of LNA and RNAi.....	42
Use of siLNA to improve siRNA.....	42
RNAi versus small molecules	42
RNAi in vivo	43
Cre-regulated RNAi in vivo	43
RNAi kits.....	43
ShortCut™ RNAi Kit.....	43
HiScribe™ RNAi Transcription Kit	44
pSUPER RNAi system.....	44
Si2 Silencing Duplex.....	45
Techniques for measuring RNAi-induced gene silencing	45
Application of PCR in RNAi.....	45
<i>Real-time quantitative PCR.....</i>	<i>46</i>
<i>Assessment of the silencing effect of siRNA by RT-PCR</i>	<i>46</i>
<i>Fluorescence resonance energy transfer probe for RNA interactions</i>	<i>47</i>
Bioinformatics tools for design of siRNAs	47
Random siRNA design.....	47

Rational siRNA design.....	48
<i>The concept of pooling siRNAs</i>	49
<i>Criteria for rational siRNA design</i>	49
<i>BLOCK-iT RNAi Designer</i>	49
<i>QIAGEN's 2-for-Silencing siRNA Duplexes</i>	50
<i>Designing vector-based siRNA</i>	50
<i>iRNAChek for designing siRNA</i>	50
<i>TROD: T7 RNAi Oligo Designer</i>	50
<i>siDirect: siRNA design software</i>	51
Prediction of efficacy of siRNAs	51
<i>Algorithms for prediction of siRNA efficacy</i>	51
<i>siRNA databases</i>	51
Production of siRNAs	52
Chemical synthesis of short oligonucleotides	52
In vitro transcription	52
Generation of siRNAs in vivo	53
UsiRNAs.....	53
siRNA:DNA hybrid molecules	54
Chemical modifications of siRNAs	54
<i>Sugar modifications of siRNA</i>	54
<i>Phosphate linkage modifications of siRNA</i>	54
<i>Modifications to the siRNA overhangs</i>	55
<i>Modifications to the duplex architecture</i>	55
<i>Applications of chemical modification of siRNAs</i>	55
Synthetic RNAs vs siRNAs	56
Specificity of siRNAs	56
Asymmetric interfering RNA	57
Genome-wide data sets for the production of esiRNAs	57
ddRNAi for inducing RNAi	57
ddRNAi technology	57
Advantages of ddRNAi over siRNA	58
Short hairpin RNAs	59
siRNA versus shRNA	59
Circular interfering RNA	60
Expressed interfering RNA	61
RNA-induced transcriptional silencing complex	61
Inhibition of gene expression by antigene RNA	62
RNAi vs mRNA modulation by small molecular weight compounds	62
saRNA for transcriptional activation	63
3. MicroRNA	64
Introduction	64
Circular RNA and miRNA	66
miRNA and RISC	66
Role of the microprocessor complex in miRNA	67
miRNAs compared to siRNAs	67
miRNA and stem cells	68
Influence of miRNA on stem cell formation and maintenance	68
Role of miRNAs in gene regulation during stem cell differentiation.....	69
miRNA databases	69
Sanger miRBase miRNA sequence database	69
Mapping miRNA genes	70
A database of ultraconserved sequences and miRNA function	71
A database for miRNA deregulation in human disease.....	71
An database of miRNA-target interactions	71
Role of miRNA in gene regulation	71
Control of gene expression by miRNA	72
<i>miRNA-mediated translational repression involving Piwi</i>	72
<i>Transcriptional regulators of ESCs control of miRNA gene expression</i>	73
Mechanism of miRNAs-induced silencing of gene expression.....	73
miRNA diagnostics	74
Biochemical approach to identification of miRNA	74
Computational approaches for the identification of miRNAs	74
LNA probes for exploring miRNA	74
miR-TRAP to identify miRNA targets in vivo.....	75
Microarrays for analysis of miRNA gene expression	75
<i>Microarrays vs quantitative PCR for measuring miRNAs</i>	76
miRNAs as biomarkers of hepatotoxicity	76
Modification of in situ hybridization for detection of miRNAs	76
Nuclease Protection Assay to measure miRNA expression.....	77
Real-time PCR for expression profiling of miRNAs.....	77

Significance of miRNAs in diagnostics	78
Targeting of miRNAs with antisense oligonucleotides	78
Silencing miRNAs by antagomirs	78
New tools for miRNA silencing	79
Use of HAPIScreen for identification of aptamers against pre-miRNAs	79
miRNA-regulated lentiviral vectors	79
miRNAs as drug targets	79
miRNAs as targets for antisense drugs	80
Challenges facing use of miRNAs as drug targets	80
Target specificity of miRNAs	81
Prediction of miRNA targets	81
Role of miRNA in human health and disease	82
Role of miRNAs in regulation of hematopoiesis	82
Role of miRNA depletion in tissue regeneration	83
Role of miRNA in regulation of aging	83
Role of miRNA in inflammation	83
Role of miRNAs in regulation of immune system	83
Role of miRNA in diabetes	84
Role of miRNA in the cardiovascular system	84
Role of miRNAs in development of the cardiovascular system	85
Role of miRNAs in angiogenesis	85
Role of miRNA in atherosclerosis	85
Role of miRNAs in cardiac hypertrophy and failure	85
Role of miRNA in cardiomyopathy	86
Role of miRNAs in conduction and rhythm disorders of the heart	87
Diagnostic and prognostic value of miRNAs in acute coronary syndrome	87
miRNA-based approaches for reduction of hypercholesterolemia	87
miRNA-based approach for restenosis following angioplasty	88
miRNA gene therapy for ischemic heart disease	88
miRNAs as therapeutic targets for cardiovascular diseases	89
Concluding remarks and future prospects of miRNA in the cardiovascular system	89
Role of miRNAs in diseases of the eye	89
Pathological ocular neovascularization	89
Role of miRNAs in diabetic retinopathy	90
Role of miRNAs in glaucoma	90
Role of miRNA in corneal scarring	90
Role of miRNAs in the nervous system	91
miRNAs and addiction	91
miRNAs in neurodegenerative disorders	92
<i>miRNAs as biomarkers of Alzheimer's disease</i>	93
<i>miRNAs in Parkinson disease</i>	94
<i>miRNAs in Huntington's disease</i>	94
<i>miRNAs in ALS</i>	95
<i>miRNAs as biomarkers of prion-induced neurodegeneration</i>	96
<i>miRNAs and retinal neurodegenerative disorders</i>	96
<i>miRNA and stroke</i>	96
<i>miRNA and schizophrenia</i>	97
Role of miRNA in neuroprotection	97
Role of miRNA in viral infections	98
Role of miRNA in HSV-1 latency	98
miRNA and autoimmune disorders	98
miRNA in rheumatoid arthritis	98
miRNA in systemic lupus erythematosus	99
miRNAs in gastrointestinal disorders	99
miRNA-based therapies for the irritable bowel syndrome	99
miRNA-based therapies for the inflammatory bowel disease	99
miRNA and skin disorders	100
Role of miRNA in inflammatory skin disorders	100
Role of miRNA in hypertrophic scarring of the skin	100
Role of miRNAs in cancer	100
miRNAs linked to the initiation and progression of cancer	101
Oncomirs	101
Linking miRNA sequences to cancer using RNA samples	102
Role of miRNAs in viral oncogenesis	102
miRNA genes in cancer	102
miRNAs interaction with p53	103
miRNAs, embryonic stem cells and cancer	104
miRNAs and cancer metastases	104
Role of miRNAs in cancer diagnosis	105
<i>Cancer miRNA signature</i>	105
<i>miRNA biomarkers in cancer</i>	105

<i>Diagnostic value of miRNA in cancer</i>	106
<i>Prognostic value of miRNA in cancer</i>	106
miRNA-based cancer therapeutics.....	106
<i>Antisense oligonucleotides targeted to miRNA</i>	107
<i>Role of miRNAs in adoptive immunotherapy of cancer</i>	107
<i>Restoration of tumor suppressor miRNAs to inhibit cancer</i>	107
<i>Delivery strategies for miRNA modulators in cancer</i>	108
Role of miRNAs in various cancers.....	109
<i>miRNA and brain tumors</i>	109
<i>miRNAs and CNS tumors in children</i>	111
<i>miRNAs and pituitary tumors</i>	112
<i>miRNA and breast cancer</i>	112
<i>miRNA and colorectal cancer</i>	113
<i>miRNA and gastrointestinal cancer</i>	114
<i>miRNA and leukemia</i>	114
<i>miRNA and lymphomas</i>	115
<i>miRNA and hepatocellular carcinoma</i>	116
<i>miRNA and lung cancer</i>	116
<i>miRNA and nasopharyngeal carcinoma</i>	118
<i>miRNA and ovarian cancer</i>	118
<i>miRNA and pancreatic cancer</i>	119
<i>miRNA and prostatic cancer</i>	119
<i>miRNA and thyroid cancer</i>	120
Companies involved in miRNA	120
Status of therapeutic development of miRNAs	122
Concluding remarks and future of miRNA therapeutics	122
4. Methods of delivery in RNAi	124
Introduction	124
Methods of delivery of oligonucleotides	124
Oral and rectal administration.....	125
Pulmonary administration.....	125
Targeted delivery to the CNS.....	126
<i>High flow microinfusion into the brain parenchyma</i>	126
Intracellular guidance by special techniques.....	126
Biochemical microinjection.....	127
Liposomes-mediated oligonucleotide delivery.....	127
Polyethylenimine-mediated oligonucleotide delivery.....	127
Delivery of TF Decoys.....	127
Biodegradable microparticles.....	128
<i>Microparticles</i>	128
<i>Nanoparticles</i>	128
Self-delivering rxRNA	129
siRNA delivery technologies	129
Local delivery of siRNA.....	130
In vivo delivery of siRNAs by synthetic vectors.....	130
Intracellular delivery of siRNAs.....	130
<i>Delivery of siRNAs with aptamer-siRNA chimeras</i>	131
<i>MPG-based delivery of siRNA</i>	132
<i>Protamine-antibody fusion proteins for delivery of siRNA to cells</i>	132
<i>Protein transduction domains</i>	132
<i>Phosphorothioate stimulated cellular delivery of siRNA</i>	133
Targeted delivery of siRNAs by lipid-based technologies.....	133
<i>Delivery of siRNA-lipoplexes</i>	133
<i>Lipidoids for delivery of siRNAs</i>	134
<i>NeoLipid™ technology</i>	134
<i>siFECTamine™</i>	134
<i>Systemic in vivo delivery of lipophilic siRNAs</i>	135
<i>Challenges and future prospects of lipid-based siRNA delivery</i>	135
Electroporation.....	135
<i>Nucleofactor technology</i>	136
<i>Visualization of electrotransfer of siRNA at single cell level</i>	136
Intravascular delivery of siRNA.....	136
27mer siRNA duplexes for improved delivery and potency.....	137
TransIT-TKO®.....	137
DNA-based plasmids for delivery of siRNA.....	138
<i>Convergent transcription</i>	139
PCR cassettes expressing siRNAs.....	139
Genetically engineered bacteria for delivery of shRNA.....	139
Viral vectors for delivery of siRNA.....	139
<i>Adenoviral vectors</i>	140

Adeno-associated virus vectors for shRNA expression	140
Baculovirus vector.....	140
Lentiviral vectors	141
Retroviral delivery of siRNA	142
Transkingdom RNAi delivery by genetically engineered bacteria.....	142
Delivery of siRNA without a vector	142
Cell-penetrating peptides for delivery of siRNAs	143
Role of nanobiotechnology in siRNA delivery	143
Chitosan-coated nanoparticles for siRNA delivery	143
Cyclodextrin nanoparticles	144
Delivery of gold nanorod-siRNA nanoplex to dopaminergic neurons	144
Lipidic aminoglycoside as siRNA nanocarrier.....	144
Lipid nanoparticles-mediated siRNA delivery.....	144
Nanoparticles for intracellular delivery of siRNA	145
Nanosize liposomes for delivery of siRNA	145
PAMAM dendrimers for siRNA delivery	146
PEG-PCL-DEX polymersome-protamine vector	146
Polyethylenimine nanoparticles for siRNA delivery	146
Polycation-based nanoparticles for siRNA delivery	147
Quantum dots to monitor siRNA delivery.....	147
siRNA-nanoparticle conjugates for improving stability in serum.....	148
Systemic delivery of siRNAi by lipid nanoparticles	148
Topical delivery of siRNA-nanoparticle conjugates	149
Targeted delivery of siRNAs to specific organs	149
siRNA delivery to the CNS.....	149
siRNA delivery to the liver.....	150
siRNA delivery to the lungs	150
Control of RNAi and siRNA levels	151
siRNA pharmacokinetics in mammalian cells	151
Mathematical modeling for determining the dosing schedule of siRNA.....	152
Assessing siRNA pharmacodynamics in animal models.....	152
Research on siRNA delivery funded by the NIH.....	152
Companies involved in delivery technologies for siRNA	153

5. RNAi in Research

Introduction	156
Basic RNAi research	156
Antiviral role of RNAi in animal cells	156
Combination of siRNA with green fluorescent protein	156
Detection of cancer mutations	157
Genes and lifespan.....	157
Inducible and reversible RNAi	157
Loss-of-function genetic screens	157
Nanoparticles mimic RNAi	158
Profiling small RNAs	158
RNAi for research in neuroscience	158
RNAi and environmental research	159
Small nucleolar RNAs	159
Study of signaling pathways.....	159
Transgenic RNAi.....	160
Use of RNAi to study insulin action	160
Applied RNAi research	160
RNAi for gene expression studies	160
Microarrays for measuring gene expression in RNAi.....	161
RNAi for functional genomic analysis	161
RNAi studies on <i>C. elegans</i>	162
RNAi studies on <i>Drosophila</i>	162
RNAi in planaria.....	163
RNAi for regenerative medicine.....	163
Testing the specificity of RNAi.....	164
Tissue-specific RNAi	164
siRNA-mediated gene silencing	164
RNAi libraries	165
Enzymatic production of RNAi library	166
Next-generation libraries for RNAi-based genome-wide screens	166
pDual library using plasmid vector	166
pHippy plasmid vector library	166
siRNA libraries using pRetroSuper vector	166
siRNA produced by enzymatic engineering of DNA.....	167
shRNA libraries	167
RNAi and alternative splicing	168

RNAi in animal development.....	168
<i>RNAi for creating transgenic animals</i>	169
<i>RNAi for creating models of neurological disorders</i>	170
Research support for RNAi in US.....	170
RNAi for toxicogenomics	170
Role of RNAi in the US biodefense research	170
The RNAi Consortium	171
Research support for RNAi in Europe.....	171
European Union for RNA Interference Technology	171
Research support of RNAi.....	172
Role of RNAi in MitoCheck project	172
RNAi Global Initiative	173
SIROCCO project.....	175
6. RNAi in drug discovery	178
Basis of RNAi for drug discovery	178
RIP-Chip for study of RNA-protein interactions.....	178
RNAi for identification of genes as therapeutic targets	179
Role of siRNAs in drug target identification	179
<i>Use of a genome-wide, siRNA library for drug discovery.....</i>	<i>180</i>
<i>Use of arrayed adenoviral siRNA libraries for drug discovery.....</i>	<i>180</i>
RNAi as a tool for assay development.....	180
Targeting human kinases with an siRNA library	180
Challenges of drug discovery with RNAi	181
Express Track SM siRNA Drug Discovery Program.....	181
Genome-wide siRNA screens in mammalian cells	182
<i>PhenomicIDTM.....</i>	<i>182</i>
Natural antisense and ncRNA as drug targets	182
RNAi for target validation.....	183
<i>Delivering siRNA for target validation in vivo</i>	<i>183</i>
<i>Validation of oncology targets discovered through RNAi screens.....</i>	<i>184</i>
<i>Selection of siRNA versus shRNA for target validation</i>	<i>185</i>
Off-target effects of siRNA-mediated gene silencing	185
<i>Bioinformatic approach to off-target effects.....</i>	<i>186</i>
<i>siPools for eliminating off-target effects of siRNAs.....</i>	<i>186</i>
<i>Managing off-target effects of vector-encoded shRNAs.....</i>	<i>186</i>
Application of RNAi to the druggable genome	187
Application of siRNA during preclinical drug development.....	187
siRNAs vs small molecules as drugs.....	188
siRNAs vs antisense drugs.....	188
Chemical modifications for improving siRNA drugs	188
RNAi technology in plants for drug discovery and development.....	189
<i>Application of RNAi to poppy plant as source of new drugs</i>	<i>189</i>
7. Therapeutic applications of RNAi	190
Introduction	190
Potential of RNAi-based therapies	191
In vitro applications of siRNA	191
In vivo applications of RNAi.....	192
RNAi and cell therapy	192
Gene inactivation to study hESCs.....	193
RNAi and stem cells	193
<i>RNAi for study of ESCs</i>	<i>194</i>
<i>RNAi and iPSCs.....</i>	<i>194</i>
Cell therapy for immune disorders	194
RNAi gene therapy.....	194
Drug-inducible systems for control of gene expression.....	195
Potential side effects of RNAi gene therapy.....	195
Systemic delivery of siRNAs	196
In vivo RNAi therapeutic efficacy in animal models of human diseases.....	196
Role of RNAi in regenerative medicine.....	197
Virus infections.....	198
RNAi approaches to viral infections.....	198
<i>Delivery of siRNAs in viral infections.....</i>	<i>199</i>
RNAi applications in HIV	199
<i>A multiple shRNA approach for silencing of HIV-1.....</i>	<i>200</i>
<i>Anti-HIV shRNA for AIDS lymphoma.....</i>	<i>200</i>
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	<i>201</i>
<i>Bispecific siRNA constructs.....</i>	<i>201</i>
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	<i>201</i>
<i>siRNA-directed inhibition of HIV-1 infection</i>	<i>202</i>

<i>Synergistic effect of snRNA and siRNA</i>	202
<i>Targeting CXCR4 with siRNAs</i>	203
<i>Targeting CCR5 with siRNAs</i>	203
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	203
Influenza	204
<i>Inhibition of influenza virus by siRNAs</i>	204
<i>Delivery of siRNA in influenza</i>	205
<i>Challenges and future prospects of siRNAs for influenza</i>	206
Respiratory syncytial and parainfluenza viruses	206
Coronavirus/severe acute respiratory syndrome	207
Herpes simplex virus 2	207
Hepatitis B	208
Hepatitis C virus	208
Cytomegalovirus	209
Virus causing hemorrhagic fever	210
<i>Dengue fever</i>	211
<i>Antivirals in development</i>	211
<i>Ebola virus</i>	212
<i>Marburg virus</i>	212
siRNA vs antisense oligonucleotides for viral infections	213
siRNA against methicillin-resistant <i>S. aureus</i>	213
RNAi-based rational approach to antimalarial drug discovery	213
Inhibiting the growth of malarial parasite by heme-binding DNA aptamers	214
siRNA-based antimalarial therapeutics	214
RNAi applications in oncology	214
Allele-specific inhibition	215
Drug delivery issues in managing cancer by RNAi approach	216
Inhibition of oncogenes	216
Modification of alternative splicing in cancer	218
Onconase	218
Overcoming drug resistance in cancer	218
<i>Targeting fusion proteins in cancer</i>	219
<i>Increasing chemosensitivity by RNAi</i>	219
RNAi approach to study TRAIL	220
RNAi-based logic circuit for identification of specific cancer cells	220
shRNA-based autologous cancer vaccine	220
siRNAs for anticancer drug discovery	221
siRNAs for inducing cancer immunity	222
siRNAs for inhibition of angiogenesis	222
siRNA targeting the R2 subunit of ribonucleotide reductase	223
siRNA for cancer chemoprevention	223
siHybrids vs siRNAs as anticancer agents	223
Nanobiotechnology-based delivery of siRNAs	224
<i>Lipid nanoparticle-based delivery of anticancer siRNAs</i>	224
<i>Minicells for targeted delivery of nanoscale anticancer therapeutics</i>	224
<i>Nanoimmunoliposome-based system for targeted delivery of siRNA</i>	224
<i>PEG-nanoparticles for delivery of siRNA to target fusion genes</i>	225
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	225
<i>RNA nanotechnology for delivery of cancer therapeutics</i>	226
<i>siRNA delivery in combination with nanochemotherapy</i>	226
<i>Targeted delivery of a nanoparticle-siRNA complex in cancer patients</i>	227
Lipophilic siRNA for targeted delivery to solid tumors	227
RNAi-based treatment of various cancer types	227
<i>RNAi-based therapy of glioblastoma multiforme</i>	227
<i>RNAi in breast cancer</i>	229
<i>RNAi for enhancing hyperthermia/chemotherapy in cervical cancer</i>	230
<i>RNAi and colorectal cancer</i>	230
<i>RNAi and Ewing's sarcoma</i>	231
<i>RNAi and leukemias</i>	231
<i>RNAi and lung cancer</i>	232
<i>RNAi and melanoma</i>	232
<i>RNAi and pancreatic cancer</i>	233
<i>RNAi and prostate cancer</i>	233
Genetic disorders	234
RNAi for skin disorders	234
Experimental studies for RNAi applications in skin disorders	234
Clinical applications of RNAi in skin disorders	235
Pachyonychia congenita	235
Skin scarring	235
Neurological disorders	236
RNAi for neurodegenerative disorders	237

<i>Alzheimer's disease</i>	237
<i>Parkinson's disease</i>	238
<i>Amyotrophic lateral sclerosis</i>	238
<i>Prion diseases</i>	239
Polyglutamine-induced neurodegeneration	240
<i>Fragile X syndrome and RNAi</i>	240
<i>RNAi-based therapy for Huntington's disease</i>	241
Combination of RNAi and gene therapy to prevent neurodegenerative disease.....	242
Role of RNAi in pain therapy.....	243
Role of RNAi in repair of spinal cord injury	243
Role of RNAi in treatment of multiple sclerosis.....	244
siRNA for Duchenne muscular dystrophy	244
siRNA for dystonia.....	244
RNAi in ophthalmology	245
Age related macular degeneration.....	245
<i>Current treatment of AMD</i>	245
<i>RNAi-based treatments for AMD</i>	246
Diabetic retinopathy	247
Retinitis pigmentosa.....	248
RNAi and metabolic disorders	248
RNAi and obesity	248
<i>Genes and regulation of body fat</i>	248
RNAi and diabetes.....	249
<i>Regulation of insulin secretion by a miRNA</i>	249
<i>RNAi for study of genes in animal models of diabetes</i>	249
<i>RNAi for drug discovery in diabetes</i>	250
<i>RNAi for treating liver dysfunction in diabetes</i>	251
<i>siRNAs for study of glucose transporter</i>	251
<i>siRNAs for targeting adipose inflammation in diabetes and obesity</i>	251
RNAi in hematology	252
Stem cell-based gene therapy and RNAi for sickle cell disease	252
Targeting of antithrombin in hemophilia with RNAi	253
RNAi and disorders of the immune system	253
siRNA applications in immunology	254
Use of RNAi in transplantation	254
RNAi for cardiovascular disorders.....	255
RNAi for hypercholesterolemia.....	255
siRNAs targeting PCSK9	255
siRNA targeting NADPH oxidase in cardiovascular diseases.....	257
Role of lncRNA in cardiovascular disorders	258
siRNA for study and treatment of ischemia-reperfusion injury	258
RNAi in respiratory disorders.....	258
siRNA for cystic fibrosis	258
siRNA for asthma	259
RNAi for musculoskeletal disorders	259
RNAi for rheumatoid arthritis.....	259
RNAi for bone disorders	261
<i>RNAi for treatment of osteoporosis</i>	261
RNAi for miscellaneous disorders	261
<i>RNAi for transthyretin amyloidosis</i>	261
Research relevant to RNAi-based therapies at academic institutes	262
Laboratory of RNA Molecular Biology, The Rockefeller University	262
RNAi Center, La Jolla Institute for Allergy & Immunology	262
Clinical trials of RNAi-based therapies	263
Improving efficacy of siRNAs for clinical trials by improved delivery.....	264
Role of RNAi in development of personalized medicine.....	264
Future of RNAi	265
Challenges for the development of RNAi-based therapeutics.....	265
8. Safety, regulatory and patent issues	268
Introduction	268
Limitations and drawbacks of RNAi	268
Adverse effects of RNAi	268
Effect of siRNAs on interferon response	269
Detection of interferon response	269
Prevention of the interferon response in RNAi.....	270
Overcoming the innate immune response to siRNAs	270
Toxicity associated with RNAi	271
Selection of siRNAs to improve specificity and efficacy.....	271
Regulatory issues relevant to RNAi.....	271
RNAi patents.....	272

Companies with strong patent position	272
Alnylam	272
Benitec	275
Intradigm	275
Quark Pharmaceuticals	275
Sirna Therapeutics	276
9. Markets for RNAi Technologies	278
Introduction	278
Current and future market potential for RNAi technologies	278
RNAi reagents	279
siRNA markets.....	279
miRNA markets	279
RNAi-based drug discovery and target validation	279
RNAi-based development of therapeutics	279
RNAi market potential according to therapeutic areas.....	280
Market for viral infections	280
Market for cancer.....	281
Market for age related macular degeneration.....	281
Unmet needs in RNAi	281
Strategies for marketing RNAi	282
Choosing optimal indications	282
Strategies according to the trends in healthcare in the next decade	283
Concluding remarks	284
10. Companies involved in RNAi Technologies	286
Introduction	286
Major players in RNAi	290
Profiles of companies.....	290
Collaborations.....	479
11. References.....	488

Tables

Table 1-1: Various types of RNA	21
Table 1-2: Classification of small RNA molecules.....	30
Table 1-3: Mechanisms of small RNAs involved in gene silencing	32
Table 1-4: Historical landmarks in the evolution of RNAi	36
Table 2-1: RNAi versus small molecules.....	43
Table 2-2: Providers of software for siRNA design	48
Table 2-3: Methods for the production of siRNAs	52
Table 2-4: Advantages and limitations of methods of shRNA-derived siRNA knockdown	60
Table 2-5: Comparison of eiRNA with siRNA	61
Table 3-1: Methods for miRNA target prediction	81
Table 3-2: miRNA expression in neurodegenerative diseases.....	93
Table 3-3: Dysregulation of miRNA expression in epithelial cancers.....	101
Table 3-4: Delivery strategies for miRNA inhibition therapies in cancer.....	108
Table 3-5: Delivery strategies for miRNA replacement to inhibit cancer growth.....	108
Table 3-6: MiRNAs and key molecules in signaling pathways in glioblastoma multiforme.....	109
Table 3-7: Companies involved in miRNA diagnostics and therapeutics	120
Table 3-8: Status of therapeutic development of miRNAs.....	122
Table 4-1: Methods of delivery of oligonucleotides	124
Table 4-2: Methods of delivery of siRNA	129
Table 4-3: Companies developing siRNA delivery technologies.....	153
Table 5-1: RNAi libraries.....	165
Table 6-1: Delivery of siRNAs in vivo for target validation	183
Table 6-2: Selection of siRNA versus shRNA for target validation	185
Table 7-1: RNAi-based therapeutic approaches.....	191
Table 7-2: In vivo RNAi therapeutic efficacy in animal models of human diseases	196
Table 7-3: Inhibition of viral replication by RNAi	199
Table 7-4: Cancer-associated genes that can be targeted by RNAi	217
Table 7-5: Neurological disorders that have been studied by using RNAi	236
Table 7-6: Clinical trials of RNAi-based therapeutics.....	263
Table 9-1: RNAi markets according to technologies and reagents 2016-2026	278
Table 9-2: Markets for RNAi therapy for selected diseases: years 2016-2026	280
Table 10-1: RNAi reagent, technology and service companies	286
Table 10-2: Pharmaceutical companies using RNAi for drug discovery and development	287
Table 10-3: Biotechnology companies using RNAi for drug discovery and development.....	288

Table 10-4: Companies developing RNAi-based therapeutic products	289
Table 10-5: Major players in RNAi.....	290
Table 10-6: Proprietary reagents of ImuThes	365
Table 10-7: Product pipeline of Silence Therapeutics	448
Table 10-8: Collaborations in RNAi technologies	479

Figures

Figure 1-1: Relationship of DNA, RNA and protein in the cell	23
Figure 1-2: Schematic of suppression of gene expression by RNAi	31
Figure 1-3: Relation of RNAi to epigenetic mechanisms	35
Figure 2-1: Overview of ShortCut RNAi Kit.....	44
Figure 2-2: Gene silencing by RNAi induced with ddRNAi	58
Figure 2-3: saRNA for targeted gene activation	63
Figure 3-1: A schematic miRNA pathway	64
Figure 3-2: Molecular mechanisms of miRNA generation	65
Figure 3-3: miRNA alternations in neurodegenerative diseases	92
Figure 4-1: RNA aptamer-mediated targeted RNAi delivery in cancer therapy.....	131
Figure 7-1: Targeting disease by RNAi.....	190
Figure 7-2: Mechanism of action of inclisiran	257
Figure 7-3: Role of RNAi in personalized medicine.....	264
Figure 8-1: Problems with use of synthetic siRNAs and measures to prevent them.....	269
Figure 9-1: Unmet needs in RNAi technologies	282